Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2013 (Event Date: January 6, 2013)
Context: The company announced key 2013-2014 goals for its RNAi therapeutics pipeline and provided an update to its cash guidance for the fiscal year ending December 31, 2012.
Key Financial Metrics
- Cash Position (Updated Guidance): Approximately $225.0 million in cash, cash equivalents, and marketable securities expected as of December 31, 2012.
- Revenue, Profit, Margins, Debt: The filing text does not provide specific values for revenue, net income, operating margins, or debt levels.
Material Changes
The primary material change disclosed is the revision of the company's cash guidance for the year ended December 31, 2012. The filing does not explicitly state the prior guidance amount or the specific variance, only the new expected figure of $225.0 million.
Guidance, Outlook, and Risks
- Outlook: Management outlined strategic goals for the 2013-2014 period regarding its RNAi therapeutics pipeline.
- Guidance Update: Cash guidance for the end of 2012 was updated to approximately $225.0 million.
- Risks and Contingencies: The filing text does not detail specific new risks or contingencies beyond the standard forward-looking statement disclaimers.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the 2013-2014 pipeline goals.
- Compare the updated $225.0 million cash guidance against the company's previous guidance to determine the magnitude of the change.
- Review the company's most recent 10-Q or 10-K for actual revenue, expense, and debt figures not included in this 8-K.